Recombinant Mouse GM-CSF protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0512



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse GM-CSF protein Ala18-Lys141 (Accession# P01587) with a His tag at the N-terminus.
GeneID 12981
Accession P01587
PredictedSize 14.9 kDa
SDS-PAGE 17-20 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

GM-CSF, also known as Csf2, is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that functions as a cytokine. GM-CSF was first characterized as a hematopoietic growth factor that stimulates the proliferation of myeloid cells from bone-marrow progenitors. GM-CSF is now recognized as an important activating and differentiation factor for immune cells, and is essential for a wide range of biological processes in both innate and adaptive immunity. GM-CSF has been shown to protect against pulmonary infection and intestinal inflammation, and it is necessary for normal pulmonary and colon homeostasis.

References:

1. Burgess AW. et al. (1977). J Biol Chem. 252:1998-2003. 2. Gasson JC. et al. (1984). Science. 94:12557-61. 3. Van Nieuwenhuijze A. et al. Mol Immunol. (2013). 56:675-82. 4. Trapnell BC. et al. (2002). Annu Rev Physiol. 64:775-802. 5. LeVine AM. et al.(1999). J Clin Inves.103:563-9.